Document:

Exhibit 10.2

 

JOINDER
AGREEMENT

 

This Joinder
Agreement (the “Joinder Agreement”) is made and dated as of June 15, 2015, and is entered into by and
between Pulmatrix, Inc. (f/k/a Ruthigen, Inc.), a Delaware corporation (“Joining
Party”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (as “Agent”).

 

RECITALS

 

A. Joining Party’s
Affiliate, which is now known as Pulmatrix Operating Company, Inc. (f/k/a Pulmatrix Inc.), a Delaware corporation (the “Company”),
has entered into that certain Loan and Security Agreement dated June 11, 2015 with the several banks and other financial institutions
or entities from time to time party thereto as lender (collectively, the “Lender”) and Agent, as such agreement
may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection
therewith.

 

B. Joining Party acknowledges
and agrees that it will benefit both directly and indirectly from the Company’s execution of the Loan Agreement and the other
agreements executed and delivered in connection therewith.

 

AGREEMENT

 

NOW THEREFORE, Joining
Party and Agent agree as follows:

 

		1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized
terms not defined herein shall have the meaning provided in the Loan Agreement.

 

		2.	By signing this Joinder Agreement, Joining Party shall be bound by the terms and conditions of
the Loan Agreement to the same extent as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis
mutandis (and pursuant hereto Joining Party confirms and agrees each representation, warranty, covenant, agreement and obligation
as a Borrower under the Loan Agreement); provided however, that (a) with respect to (i) Section 5.1 of the Loan Agreement,
Joining Party represents that it is an entity duly organized, legally existing and in good standing under the laws of Delaware,
(b) neither Agent nor Lender shall have any duties, responsibilities or obligations to Joining Party arising under or related to
the Loan Agreement or the other agreements executed and delivered in connection therewith, and (c) if Joining Party is covered
by the Company’s insurance, Joining Party shall not be required to maintain separate insurance or comply with the provisions
of Sections 2.5, 6.1 and 6.2 of the Loan Agreement, and (d) from and after the date hereof, the requirements of Section 7.1 of
the Loan Agreement shall be satisfied by delivery of the consolidated financial statements of Joining Party. To the extent that
Agent or Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements
executed and delivered in connection therewith, those duties, responsibilities or obligations shall flow only to the Company and
not to Joining Party or any other Person (as defined in the Loan Agreement). By way of example (and not an exclusive list): (i)
Agent’s providing notice to the Company in accordance with the Loan Agreement or as otherwise agreed among the Company, Agent
and Lender shall be deemed provided to Joining Party; (ii) a Lender’s providing an Advance to the Company shall be deemed
an Advance to Joining Party.

 

    	 

    	 

    

  

		3.	Joining Party acknowledges that it benefits, both directly and indirectly, from the Loan Agreement,
and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee for
the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy proceeding) to the
fullest extent provided by law, any and all claims, rights or defenses to the enforcement of this Joinder Agreement on the basis
that (a) it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b) its obligations
under this Joinder Agreement are avoidable as a fraudulent conveyance.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

 

    	 

    	 

    

  

[SIGNATURE PAGE TO JOINDER
AGREEMENT]

 

Joining
Party:

 

			

	
         

         
	PULMATRIX, INC. (f/k/a Ruthigen, Inc.)
	 	By:  	/s/ Robert W. Clarke, Ph.D.
	 	Name:  	Robert W. Clarke, Ph.D.
	 	Title:  	Chief Executive Officer

 

		Address:	

 

	 	PULMATRIX INC.
	 	99 Hayden Avenue
	 	Suite 390
	 	Lexington, MA 02421
	 	Attention: Dr. Robert Clarke
	 	Email: rclarke@Pulmatrix.com
	 	Telephone: 781-357-2333

 

AGENT:

 

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

 

	
         

        
	By:	/s/ Christine Fera
	 	Name:	Christine Fera
	 	Title:	Director of Contract Originations

 

	 	Address:
	 	 
	 	400 Hamilton Ave., Suite 310
	 	Palo Alto, CA 94301
	 	Facsimile: 650-473-9194
	 	Telephone: 650-289-3060Exhibit 10.3

 

Execution Version

 

THIS WARRANT AND THE SHARES ISSUABLE UPON
EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES
LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.

 

WARRANT AGREEMENT

 

To Purchase Shares of the Common Stock of

 

PULMATRIX, INC.

 

Dated as of June 16, 2015 (the “Effective
Date”)

 

WHEREAS, Pulmatrix,
Inc. (formerly known as Ruthigen, Inc.), a Delaware corporation (the “Company”), on the date hereof, has become
party to that certain Loan and Security Agreement, dated as of June 11, 2015, among an entity now known as Pulmatrix Operating
Company, Inc., a Delaware corporation, Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Warrantholder”),
in its capacity as administrative agent and lender, and the lender parties thereto (the “Loan Agreement”).

 

WHEREAS, pursuant to
the Loan Agreement, and as additional consideration to the Warrantholder for, among other things, its agreements in the Loan Agreement,
the Company has agreed to issue to the Warrantholder this Warrant Agreement (the “Agreement”), evidencing the
right to purchase shares of Common Stock of the Company (the “Warrant).

 

NOW, THEREFORE, in
consideration of the Warrantholder having executed and delivered the Loan Agreement and provided the financial accommodations contemplated
therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows:

 

SECTION 1.      GRANT OF
THE RIGHT TO PURCHASE COMMON STOCK

 

(a)          For
value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to
the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to the number of fully paid and non-assessable
shares of Common Stock (as defined below) as determined pursuant to Section 1(b) below, at a purchase price per share equal
to the Exercise Price (as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in
Section 8. As used herein, the following terms shall have the following meanings:

 

“Charter”
means the Company’s Certificate of Incorporation, as may be amended and in effect from time to time.

 

“Common Stock”
means the Company’s common stock, $0.0001 par value per share, as presently constituted under the Charter, and any class
and/or series of Company capital stock for or into which such common stock may be converted or exchanged in a reorganization, recapitalization
or similar transaction.

 

    	 

    	Execution Version

    

  

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“Exercise Price”
means $8.35, subject to adjustment from time to time in accordance with the provisions of this Agreement.

 

“Liquid Sale”
means the closing of a Merger Event in which the consideration received by the Company and/or its stockholders, as applicable,
consists solely of cash and/or Marketable Securities.

 

“Marketable
Securities” in connection with a Merger Event means securities meeting all of the following requirements: (i) the issuer
thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Exchange Act, and is then current in
its filing of all required reports and other information under the Securities Act (as defined below) and the Exchange Act; (ii)
the class and series of shares or other security of the issuer that would be received by the Warrantholder in connection with the
Merger Event were the Warrantholder to exercise this Warrant on or prior to the closing thereof is then traded on a national securities
exchange or over-the-counter market, and (iii) following the closing of such Merger Event, Warrantholder would not be restricted
from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Warrantholder in such
Merger Event were Warrantholder to exercise this Warrant in full on or prior to the closing of such Merger Event, except to the
extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not
extend beyond six (6) months from the closing of such Merger Event.

 

“Merger Event”
means any of the following: (i) a sale, lease or other transfer of all or substantially all assets of the Company, (ii) any merger
or consolidation involving the Company in which the Company is not the surviving entity or in which the outstanding shares of the
Company’s capital stock are otherwise converted into or exchanged for shares of capital stock or other securities or property
of another entity and in which the holders of a majority of the outstanding shares of capital stock of the Company immediately
prior to such merger or consolidation do not hold a majority of the surviving entity or other entity immediately following such
merger or consolidation, or (iii) any sale by holders of the outstanding voting equity securities of the Company in a single transaction
or series of related transactions of shares constituting a majority of the outstanding combined voting power of the Company.

 

“Purchase Price”
means, with respect to any exercise of this Warrant, an amount equal to the Exercise Price (subject to adjustment from time to
time in accordance with the provisions of this Agreement) multiplied by the number of shares of Common Stock as to which this Warrant
is then exercised.

 

“Rule 144”
means Rule 144 of the Securities Act, as amended.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

(b)          Number
of Shares. This Warrant shall be exercisable for 25,150 shares of Common Stock, subject to adjustment from time to time
in accordance with the provisions of this Agreement, subject to further adjustment thereafter from time to time in accordance with
the provisions of this Agreement.

 

    	 

    	Execution Version

    

  

SECTION 2.      TERM
OF THE AGREEMENT

 

The term of this Agreement
and the right to purchase Common Stock as granted herein shall commence on the Effective Date and, subject to Section 8(a),
shall be exercisable for a period ending upon the fifth (5th) anniversary of the Effective Date.

 

SECTION 3.      EXERCISE
OF THE PURCHASE RIGHTS

 

(a)          Exercise.
The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or from
time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office
a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed
and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms
set forth below, and in no event later than three business (3) days thereafter, the Company shall cause its transfer agent to issue
to the Warrantholder in book entry form the number of shares of Common Stock purchased, and the Company shall execute the acknowledgment
of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the
number of shares which remain subject to future purchases under this Agreement, if any.

 

 

The Purchase Price
may be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the
Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an amended Agreement setting forth
the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”). If the Warrantholder
elects the Net Issuance method, the Company will issue shares of Common Stock in accordance with the following formula:

 

X = Y(A-B)

    A

 

Where:  
   X = the number of shares of Common Stock to be issued to the Warrantholder.

 

Y = the number of shares of
Common Stock requested to be exercised under this Agreement.

 

A = the then-current fair
market value of one (1) share of Common Stock at the time of exercise.

 

B = the then-effective Exercise
Price.

 

For purposes of the
above calculation, the current fair market value of shares of Common Stock shall mean with respect to each share of Common Stock:

 

		(i)	at all times when the Common Stock is traded on a national securities exchange, inter-dealer quotation
system or over-the-counter bulletin board service, the average of the closing prices over a five (5) day period ending three days
before the day the current fair market value of the securities is being determined;

 

    	 

    	Execution Version

    

  

		(ii)	if the exercise is in connection with a Merger Event, the fair market value of a share of Common
Stock shall be deemed to be the per share value received by the holders of the outstanding shares of Common Stock pursuant to such
Merger Event as determined in accordance with the definitive transaction documents executed among the parties in connection therewith;
or

 

		(iii)	in cases other than as described in the foregoing clauses (i) and (ii), the current fair market
value of a share of Common Stock shall be determined in good faith by the Company’s Board of Directors, unless the Company
shall become subject to a Merger Event, in which case the fair market value of shares of Common Stock shall be deemed to be the
per share value received by the holders of the Common Stock on a common equivalent basis pursuant to such Merger Event.

 

Upon partial exercise by either cash or, upon
request by the Warrantholder and surrender of all or a portion of this Warrant, Net Issuance, prior to the expiration or earlier
termination hereof, the Company shall promptly issue an amended Agreement representing the remaining number of shares purchasable
hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but
not limited to the Effective Date hereof.

 

(b)          Exercise
Prior to Expiration. To the extent this Warrant is not previously exercised as to all shares subject hereto, and if the then-current
fair market value is greater than the Exercise Price then in effect, or, in the case of a Liquid Sale, where the value per share
of Common Stock (as determined as of the closing of such Liquid Sale in accordance with the definitive agreements executed by the
parties in connection with such Merger Event) to be paid to the holders thereof is greater than the Exercise Price then in effect,
this Agreement shall be deemed automatically exercised on a Net Issuance basis pursuant to Section 3(a) (even if not surrendered)
as of immediately before its expiration determined in accordance with Section 2. For purposes of such automatic exercise,
the fair market value of one share of Common Stock upon such expiration shall be determined pursuant to Section 3(a). To
the extent this Warrant or any portion hereof is deemed automatically exercised pursuant to this Section 3(b), the Company
agrees to promptly notify the Warrantholder of the number of shares of Common Stock if any, the Warrantholder is to receive by
reason of such automatic exercise, and to cause its transfer agent to issue such shares to Warrantholder in book entry form evidencing
such shares.

 

SECTION 4.      RESERVATION
OF SHARES

 

During the term of
this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Common Stock to
provide for the exercise of the rights to purchase Common Stock as provided for herein.

 

SECTION 5.      NO
FRACTIONAL SHARES OR SCRIP

 

No fractional shares
or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares
the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect.

 

    	 

    	Execution Version

    

  

SECTION 6.      NO
RIGHTS AS STOCKHOLDER

 

Without limitation
of any provision hereof, Warrantholder agrees that this Agreement does not entitle the Warrantholder to any voting rights or other
rights as a stockholder of the Company prior to the exercise of any of the purchase rights set forth in this Agreement.

 

SECTION 7.      WARRANTHOLDER
REGISTRY

 

The Company shall maintain
a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s initial address, for
purposes of such registry, is set forth in Section 12(g). Warrantholder may change such address by giving written notice
of such changed address to the Company.

 

SECTION 8.      ADJUSTMENT
RIGHTS

 

The Exercise Price
and the number of shares of Common Stock purchasable hereunder are subject to adjustment from time to time, as follows:

 

(a)          Merger
Event. In connection with a Merger Event that is a Liquid Sale, this Warrant shall, on and after the closing thereof, automatically
and without further action on the part of any party or other person, represent the right to receive the consideration payable on
or in respect of all shares of Common Stock that are issuable hereunder as of immediately prior to the closing of such Merger Event
less the Purchase Price for all such shares of Common Stock (such consideration to include both the consideration payable at the
closing of such Merger Event and all deferred consideration payable thereafter, if any, including, but not limited to, payments
of amounts deposited at such closing into escrow and payments in the nature of earn-outs, milestone payments or other performance-based
payments), and such Merger Event consideration shall be paid to Warrantholder as and when it is paid to the holders of the outstanding
shares of Common Stock. In connection with a Merger Event that is not a Liquid Sale, the Company shall cause the successor or surviving
entity to assume this Agreement and the obligations of the Company hereunder on the closing thereof, and thereafter this Warrant
shall be exercisable for the same number and type of securities or other property as the Warrantholder would have received in consideration
for the shares of Common Stock issuable hereunder had it exercised this Warrant in full as of immediately prior to such closing,
at an aggregate Exercise Price no greater than the aggregate Exercise Price in effect as of immediately prior to such closing,
and subject to further adjustment from time to time in accordance with the provisions of this Agreement. The provisions of this
Section 8(a) shall similarly apply to successive Merger Events.

 

(b)          Reclassification
of Shares. Except for Merger Events subject to Section 8(a), if the Company at any time shall, by combination, reclassification,
exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement
exist into the same or a different number of securities of any other class or classes of securities, this Agreement shall thereafter
represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with
respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination,
reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly apply to successive
combination, reclassification, exchange, subdivision or other change.

 

(c)          Subdivision
or Combination of Shares. If the Company at any time shall combine or subdivide its Common Stock, (i) in the case of a subdivision,
the Exercise Price shall be proportionately decreased and the number of shares for which this Warrant is exercisable shall be proportionately
increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased and the number of shares
for which this Warrant is exercisable shall be proportionately decreased.

 

    	 

    	Execution Version

    

  

(d)          Dividends.
If the Company at any time while this Agreement is outstanding and unexpired shall:

 

		(i)	pay a dividend with respect to the outstanding shares of Common Stock payable in additional shares
of Common Stock, then the Exercise Price shall be adjusted, as of the record date applicable to such dividend, to that price determined
by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of
which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B)
the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution,
and the number of shares of Common Stock for which this Warrant is exercisable shall be proportionately increased; or

 

		(ii)	make any other dividend or distribution on or with respect to Common Stock, except any dividend
or distribution (A) in cash, or (B) specifically provided for in any other clause of this Section 8, then, in each such
case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise of this Warrant a proportionate
share of any such distribution as though it were the holder of the Common Stock as of the record date fixed for the determination
of the shareholders of the Company entitled to receive such distribution.

 

(e)          Notice
of Certain Events. If: (i) the Company shall declare any dividend or distribution upon its outstanding Common Stock, payable
in stock, cash, property or other securities (provided that Warrantholder in its capacity as lender under the Loan Agreement consents
to such dividend); (ii) the Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares
of stock of any class or other rights; (iii) there shall be any Merger Event; or (iv) there shall be any voluntary dissolution,
liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice
thereof at the same time and in the same manner as it gives notice thereof to the holders of outstanding Common Stock.

 

SECTION 9.      REPRESENTATIONS, WARRANTIES AND COVENANTS
OF THE COMPANY

 

(a)          Reservation
of Common Stock. The Company covenants and agrees that all shares of Common Stock, if any, that may be issued upon the exercise
of this Warrant will, upon issuance, be validly issued and outstanding, fully paid and non-assessable. The Company further covenants
and agrees that the Company will, at all times during the term hereof, have authorized and reserved, free from preemptive rights,
a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any
time during the term hereof the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise
of this Warrant in full, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase
its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes.

 

    	 

    	Execution Version

    

  

(b)          Due
Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock, have been duly authorized
by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Company’s Charter
or current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) except as
could not reasonably be expected to have a Material Adverse Effect (as defined in the Loan Agreement), does not and will not contravene
any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or
by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance
with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting
creditors’ rights generally (including, without limitation, fraudulent conveyance laws) and by general principles of equity,
regardless of whether considered in a proceeding in equity or at law.

 

(c)          Consents
and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect
of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance
by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Securities
Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby.

 

(d)          Exempt
Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the
Common Stock upon exercise of this Agreement will constitute a transaction exempt from (i) the registration requirements of Section
5 of the Securities Act, in reliance upon Section 4(a)(2) thereof, and (ii) the qualification requirements of the applicable state
securities laws.

 

(e)          Information
Rights. At all times (if any) prior to the earlier to occur of (x) the date on which all shares of Common Stock issued on exercise
of this Warrant have been sold, or (y) the expiration or earlier termination of this Agreement, when the Company shall not be required
to file reports pursuant to Section 13 or 15(d) of the Exchange Act or shall not have timely filed all such required reports, Warrantholder
shall be entitled to the information rights contained in Section 7.1(b) — (f) of the Loan Agreement, and in any such event
Section 7.1(b) — (f) of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set
forth herein, provided, however, that the Company shall not be required to deliver a Compliance Certificate once
all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid.

 

(f)          Rule
144 Compliance. The Company shall, at all times prior to the earlier to occur of (x) the date of sale or other disposition
by Warrantholder of this Warrant or all shares of Common Stock issued on exercise of this Warrant, or (y) the expiration or earlier
termination of this Agreement if the Warrant has not been exercised in full or in part on such date, use all commercially reasonable
efforts to timely file all reports required under the Exchange Act and otherwise timely take all actions necessary to permit the
Warrantholder to sell or otherwise dispose of this Warrant and the shares of Common Stock issued on exercise hereof pursuant to
Rule 144 and in effect from time to time, provided that the foregoing shall not apply in the event of a Merger Event following
which the successor or surviving entity is not subject to the reporting requirements of the Exchange Act. If the Warrantholder
proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance with Rule 144, then, upon Warrantholder’s
written request to the Company, the Company shall furnish to the Warrantholder, within five (5) business days after receipt of
such request, a written statement confirming the status of the Company’s compliance with the filing and other requirements
of such Rule.

 

    	 

    	Execution Version

    

  

SECTION 10.    REPRESENTATIONS
AND COVENANTS OF THE WARRANTHOLDER

 

This Agreement has
been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder:

 

(a)          Investment
Purpose. This Warrant and the shares issued on exercise hereof will be acquired for investment and not with a view to the sale
or distribution of any part thereof in violation of applicable federal and state securities laws, and the Warrantholder has no
present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption.

 

(b)          Private
Issue. The Warrantholder understands (i) that the Common Stock issuable upon exercise of this Agreement is not, as of the Effective
Date, registered under the Securities Act or qualified under applicable state securities laws, and (ii) that the Company’s
reliance on exemption from such registration is predicated on the representations set forth in this Section 10.

 

(c)          Financial
Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its investment, and has the ability to bear the economic risks of its investment in the Company.

 

(d)          Accredited
Investor. Warrantholder is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated
under the Securities Act, as presently in effect (“Regulation D”).

 

(e)          No
Short Sales. Warrantholder has not at any time on or prior to the Effective Date engaged in any short sales or equivalent
transactions in the Common Stock. Warrantholder agrees that at all times from and after the Effective Date and on or before the
expiration or earlier termination of this Agreement, it shall not engage in any short sales or equivalent transactions in the Common
Stock.

 

SECTION 11.    TRANSFERS

 

Subject to compliance
with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or in part,
without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker
and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall
be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on
the Company’s books, shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner
hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement
shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as
Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer
taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may
treat the registered owner hereof as the owner for all purposes. Notwithstanding anything herein or in any legend to the contrary,
(i) the Company shall not require an opinion of counsel in connection with any sale, assignment or other transfer, by Warrantholder
of this Warrant (or any portion hereof or any interest herein) to an affiliate (as defined in Regulation D) of Warrantholder, provided
that such affiliate is an “accredited investor” as defined in Regulation D.

 

    	 

    	Execution Version

    

  

SECTION 12.    MISCELLANEOUS.

 

(a)          Effective
Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed
and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company.

 

(b)          Remedies.
In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in
equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action
for specific performance for any default where the non-defaulting party will not have an adequate remedy at law and where damages
will not be readily ascertainable.

 

(c)          No
Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid
the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying
out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of
the Warrantholder against impairment.

 

(d)          Additional
Documents. The Company agrees to supply such other documents as the Warrantholder may from time to time reasonably request.

 

(e)          Attorneys’
Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing
party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this
Agreement. For the purposes of this Section 12(e), attorneys’ fees shall include without limitation fees incurred
in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any
kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment
motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment.

 

(f)          Severability.
In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable,
the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced
by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying
the invalid, illegal or unenforceable provision.

 

(g)          Notices.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication
that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing,
and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (a) personal delivery to the
party to be notified, (b) when sent by confirmed telex, electronic transmission or facsimile if sent during normal business hours
of the recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified mail,
return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt, and shall be addressed to the party to be notified as follows:

 

    	 

    	Execution Version

    

 

If to Warrantholder:

 

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

Legal Department

Attention: Deputy General Counsel and Manuel Henriquez

400 Hamilton Avenue, Suite 310

Palo Alto, California 94301

Facsimile: 650-473-9194

Telephone: 650-289-3060

Email: legal@herculestech.com

 

If to the Company:

 

Pulmatrix, Inc.

Attention: Chief Financial Officer

99 Hayden Avenue, Suite 390

Lexington, MA 02421

Facsimile: (781) 357-2356

Telephone: (781) 357-2399

Email: msiegert@pulmatrix.com

 

With a copy to (which shall not constitute notice):

 

Haynes and Boone, LLP

30 Rockefeller Plaza

New York, New York 10112

Attn: Rick A. Werner, Esq.

E-mail: rick.werner@haynesboone.com

 

or to such other address as each party may designate for itself
by like notice.

 

(h)          Entire
Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of
the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations
or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the terms of this
Agreement may be amended except by an instrument executed by each of the parties hereto.

 

(i)          Headings.
The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of
this Agreement or any provisions hereof.

 

(j)          No
Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.

 

    	 

    	Execution Version

    

  

(k)          No
Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance
of any of the terms, covenants or provisions hereof by Warrantholder at any time designated, shall be a waiver of any such right
or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions
thereafter during the term of this Agreement.

 

(l)          Survival.
All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be
for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination
of this Agreement.

 

(m)          Governing
Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California,
excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 

(n)          Consent
to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement,
each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, State of California;
(b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense
based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered
thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this
Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall
be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in
any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

 

(o)          Mutual
Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically
resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration
rules), the parties desire that their disputes arising under or in connection with this Agreement be resolved by a judge applying
such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE
OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED
BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY RELATING TO THIS AGREEMENT.
This waiver extends to all such Claims, including Claims that involve persons or entities other the Company and Warrantholder;
Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims
for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement.

 

(p)          Arbitration.
If the Mutual Waiver of Jury Trial set forth in Section 12(p) is ineffective or unenforceable, the parties agree that all
Claims shall be submitted to binding arbitration in accordance with the commercial arbitration rules of JAMS (the “Rules”),
such arbitration to occur before one arbitrator, which arbitrator shall be a retired California state judge or a retired Federal
court judge. Such proceeding shall be conducted in Santa Clara County, State of California, with California rules of evidence and
discovery applicable to such arbitration. The decision of the arbitrator shall be binding on the parties, and shall be final and
nonappealable to the maximum extent permitted by law. Any judgment rendered by the arbitrator may be entered in a court of competent
jurisdiction and enforced by the prevailing party as a final judgment of such court.

 

    	 

    	Execution Version

    

  

(q)          Pre-arbitration
Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction
identified in Section 12(n), any prejudgment order, writ or other relief and have such prejudgment order, writ or other
relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by binding
arbitration.

 

(r)          Counterparts.
This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts (including
by facsimile or electronic delivery (PDF)), and by different parties hereto in separate counterparts, each of which when so delivered
shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.

 

(s)          Specific
Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to Warrantholder
by reason of the Company’s failure to perform any of the obligations under this Agreement and agree that the terms of this
Agreement shall be specifically enforceable by Warrantholder. If Warrantholder institutes any action or proceeding to specifically
enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense
therein that Warrantholder has an adequate remedy at law, and such person shall not offer in any such action or proceeding the
claim or defense that such remedy at law exists.

 

(t)          Lost,
Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms
as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such
new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated
or destroyed Warrant shall be at any time enforceable by anyone.

 

(u)          Legends.
To the extent required by applicable laws, this Warrant and the shares of Common Stock issuable hereunder (and the securities issuable,
directly or indirectly, upon conversion of such shares of Common Stock, if any) may be imprinted with a restricted securities legend
in substantially the following form:

 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR
OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT
TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

[Remainder of Page Intentionally Left
Blank]

 

    	 

    	Execution Version

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed by its officers thereunto duly authorized as of the Effective Date.

 

	COMPANY: 	PULMATRIX, INC. 
	 	 	 
	 	By:	/s/ Robert W. Clarke, Ph.D.
	 	 	 
	 	Name: 	Robert W. Clarke, Ph.D.
	 	 	 
	 	Title:	Chief Executive Officer

 

	WARRANTHOLDER:	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
	 	 	 
	 	By:	/s/ Christine Fera
	 	 	 
	 	Name: 	Christine Fera
	 	 	 
	 	Title:	Director of Contract Originations

 

[Signature Page
to Warrant]

  

    	 

    	Execution Version

    

 

EXHIBIT I

 

FORM OF

NOTICE OF EXERCISE

 

To: [ ]

 

		(1)	The undersigned Warrantholder hereby elects to purchase [ ] shares of the Common Stock of [ ], pursuant to the terms of the
Agreement dated the [ ] day of [ , ] (the “Agreement”) between [ ] and the Warrantholder, and tenders herewith payment
of the Purchase Price in full, together with all applicable transfer taxes, if any. [NET ISSUANCE: elects pursuant to Section 3(a)
of the Agreement to effect a Net Issuance.]

 

		(2)	Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such
other name as is specified below.

 

	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)

 

	WARRANTHOLDER: 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
	 	 
	 	By:
	 	 
	 	Name:
	 	 
	 	Title:

 

    	 

    	Execution Version

    

 

EXHIBIT II

 

1. ACKNOWLEDGMENT OF
EXERCISE

 

The undersigned [ ], hereby acknowledge receipt of the “Notice
of Exercise” from Hercules Technology Growth Capital, Inc. to purchase [ ] shares of the Common Stock of [ ], pursuant to
the terms of the Warrant, and further acknowledges that [ ] shares remain subject to purchase under the terms of the Warrant.

 

	COMPANY: 	PULMATRIX, INC. 
	 	 	 
	 	By:	 
	 	 	 
	 	Title: 	 
	 	 	 
	 	Date:	 

 

    	 

    	Execution Version

    

 

EXHIBIT III

 

TRANSFER NOTICE

 

(To transfer or assign
the foregoing Warrant execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby transferred and assigned to

 

	(Please Print)	 
	 	 
	whose address is	 
	 	 
	 	Dated:
	 	 
	 	Holder’s Signature:
	 	 
	 	Holder’s Address:
	 	 
	Signature Guaranteed:	 
	 	 

 

NOTE: The signature to this Transfer Notice
must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]